CLOs on the Move

Vanda Pharmaceuticals

www.vandapharmaceuticals.com

 
Vanda Pharmaceuticals (NASDAQ: VNDA) is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders to address unmet needs. The company has assembled an experienced team along with a portfolio of clinical and commercial stage programs with the goal of bringing important new treatment options to patients.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

SNBL USA

SNBL USA is a part of the SNBL Group of companies and is a subsidiary of Shin Nippon Biomedical Laboratories (SNBL). As part of the SNBL Group, SNBL USA shares the corporate mission statement: We are committed to freeing patients from suffering by

The Institute for Family Health

The Institute for Family Health is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. The Institute for Family Health is based in New York, NY. You can find more information on The Institute for Family Health at www.institute2000.org

Preferred Health Systems

Preferred Health Systems is a Wichita, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Co-Bio Consulting

Co-Bio Consulting is a Acton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Berg LLC

BERG is a Boston-based biopharma company focused on taking a bold “back to biology” approach to therapeutic discovery using its unique AI-based Interrogative Biology® platform. This platform combines patient biology and AI-based analytics to engage the differences between healthy and disease environments. The patient’s own biology drives the platform’s results and guides us in the discovery and development of drugs, diagnostics and healthcare applications. Our platform utilizes patient population health data to bring actionable Patient IntelligenceTM to precision medicine applications. For patients this means faster discovery and development of treatments, more effective precision treatments for individuals as well as a reduction in costs to our healthcare systems. BERG has a robust product portfolio in oncology, endocrinology and neurology with mature assets in oncology entering mid and late stage trials. BERG is committed to improving the lives of patients through precision medicine made possible by our innovative platforms.